NSF Names Thomas Glasgow, Jr. Board Chairman

NSF, a leading global public health and safety organization, today announced Thomas Glasgow, Jr. as its new Board Chairman. Glasgow succeeds Richard E. Rabbideau, J.D., who has held the Chairman role since 1992.

Thomas Glasgow has been an active member of NSF’s Board of Directors since 1990 and will now bring decades of leadership to his new position as the Board Chairman.

“After many years of dedicated board service, we are honored to confirm Thomas Glasgow, Jr. as NSF’s Board Chairman,” said Pedro Sancha, President and CEO, NSF. “We welcome his organizational knowledge and keen strategic insights as we look forward to taking our mission of improving human and planet health to new heights in 2023 and beyond. In the same breath, I want to extend my gratitude to Richard Rabbideau for his years of leadership and guidance.”

Thomas Glasgow enjoyed a 30-year career with McDonald’s Corporation, serving his last six as Executive Vice President and Chief Operations Officer globally. He has since served on numerous private and not-for-profit boards.

Glasgow holds a Bachelors in Business Administration, Management and Operations from Michigan State University and lives in North Carolina.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.